Hear what experts and patients have to say

Missing the Mark in CML

7 min 15 sec watch

Moshe Talpaz, MD, and Eri Matsuki, MD, discuss tolerability issues in later lines of chronic myeloid leukemia (CML) and when a treatment switch may be necessary.

Overcoming Resistance

8 min 3 sec watch

Jorge Cortes, MD, and Carla Boquimpani, MD, analyze the consequences of treatment resistance in later lines of chronic myeloid leukemia (CML).

Choosing What to Change in CML

7 min 12 sec watch

Valentin Garcia Gutierrez, MD, PhD, and Gabriela Hobbs, MD, review case studies and discuss different management strategies for patients experiencing TKI intolerance.

Approaches in Patient Management

8 min 2 sec watch

Javier Pinilla-Ibarz, MD, PhD, and Antonio Almeida, MD, explore considerations for sequential TKI use in patients with CML.

FAQ: What Is the Most Common HCP Question About CML?

58 sec watch

Jorge Cortes, MD, discusses the most common question HCPs ask him: "When a patient with CML is resistant to treatment, what do I do next?"

FAQ: Is CML Solved?

50 sec watch

Javier Pinilla-Ibarz, MD, PhD, shares his perspective on the need for new treatments for patients in later lines of chronic myeloid leukemia (CML).

FAQ: Is Switching Due to Low Grade AEs Appropriate?

1 min 7 sec watch

Moshe Talpaz, MD, talks about the importance of considering low-grade AEs when it comes to treating patients in later lines of CML.

FAQ: What Are the Warning Signs of Resistance?

1 min 13 sec watch

Jorge Cortes, MD, explains how to identify the clinical signs of resistance in patients in later lines of chronic myeloid leukemia (CML).

FAQ: Dose Adjustment or Switch?

1 min 18 sec watch

Jorge Cortes, MD, discusses how to approach different clinical scenarios for patients in later lines of therapy for CML.